2020

1. Systemic rituximab for the treatment of the indolent forms of primary cutaneous B-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

   Journal of the American Academy of Dermatology, Vol. 83, Núm. 5, pp. 1535-1538